A Vision for the Future of Science Philanthropy
By Evan S. Michelson and Adam F. Falk,
Issues in Science and Technology
| 11. 09. 2021
Although we can envision many ways that the scientific enterprise might evolve in the future, an often-overlooked component will surely play an essential role: science philanthropy. By this we mean the provision of charitable giving for science or technology research by individual donors or foundations. As Robert Conn, past president and chief executive officer of The Kavli Foundation, details in his overview of the emergence of philanthropic giving for research, science philanthropy has always played a critical and leading role in America’s approach to research and development, with a history that predates much of the federal funding apparatus.
Today, the landscape of science philanthropy is rapidly changing. It consists of both established and newer foundations, a constellation of institutions including organizations with an illustrious history of giving for research as well as entities created more recently. Collectively, science philanthropy accounts for at least $2 billion in annual support for research. If we include spending from university endowments that supports research at those institutions, the total impact of philanthropy on science is estimated to be as much as $20 billion per...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Alex Aylward, Daniel J. Fairbanks, Maria Kiladi, and Gregory Radick , Heredity | 04.20.2026
Genetics and eugenics co-evolved at the beginning of the twentieth century and remained associated through the 1940s and beyond. Early geneticists were far from unanimous in their views on eugenics; some avidly supported the movement, whereas others openly opposed it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...